Comparison of long-term efficacy and safety of blonanserin treatment in individuals with first-episode and relapsed schizophrenia: a 3-year retrospective study

References

• Casey DE. Long-term treatment goals: enhancing healthy outcomes. CNS Spectr. 2003;8(11 Suppl 2):26–28.
   Web of Science ®Google Scholar
• Kishimoto T, Agarwal V, Kishi T, et al. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Mol Psychiatry. 2013;18(1):53–66.
   PubMed Web of Science ®Google Scholar
• Hui CL, Tang JY, Leung CM, et al. A 3-year retrospective cohort study of predictors of relapse in first-episode psychosis in Hong Kong. Aust N Z J Psychiatry. 2013;47(8):746–753.
   PubMed Web of Science ®Google Scholar
• Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56(3):241–247.
   PubMed Web of Science ®Google Scholar
• Robinson DG, Woerner MG, Alvir JM, et al. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr Res. 2002;57(2–3):209–219.
   PubMed Web of Science ®Google Scholar
• Malow BA, Connolly HV, Weiss SK, et al. The Pediatric Sleep Clinical Global Impressions Scale – a new tool to measure pediatric insomnia in autism spectrum disorders. J Dev Behav Pediatr. 2016;37(5):370–376.
   Web of Science ®Google Scholar
• Fusar-Poli P, McGorry PD, Kane JM. Improving outcomes of first-episode psychosis: an overview. World Psychiatry. 2017;16(3):251–265.
   PubMed Web of Science ®Google Scholar
• Jarskog LF, Mattioli MA, Perkins DO, et al. First-episode psychosis in a managed care setting: clinical management and research. Am J Psychiatry. 2000;157(6):878–884.
   Web of Science ®Google Scholar
• Robinson DG, Woerner MG, Delman HM, et al. Pharmacological treatments for first-episode schizophrenia. Schizophr Bull. 2005;31(3):705–722.
   PubMed Web of Science ®Google Scholar
• Uzenoff SR, Penn DL, Graham KA, et al. Evaluation of a multi-element treatment center for early psychosis in the United States. Soc Psychiatry Psychiatr Epidemiol. 2012;47(10):1607–1615.
   Web of Science ®Google Scholar
• Higashi K, Medic G, Littlewood KJ, et al. Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Ther Adv Psychopharmacol. 2013;3(4):200–218.
   PubMedGoogle Scholar
• Adelufosi AO, Adebowale TO, Abayomi O, et al. Medication adherence and quality of life among Nigerian outpatients with schizophrenia. Gen Hosp Psychiatry. 2012;34(1):72–79.
   Web of Science ®Google Scholar
• Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull. 1997;23(4):637–651.
   PubMed Web of Science ®Google Scholar
• Gilbert PL, Harris MJ, McAdams LA, et al. Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Arch Gen Psychiatry. 1995;52(3):173–188.
   PubMed Web of Science ®Google Scholar
• Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63(10):892–909.
   PubMed Web of Science ®Google Scholar
• Carder PC, Vuckovic N, Green CA. Negotiating medications: patient perceptions of long-term medication use. J Clin Pharm Ther. 2003;28(5):409–417.
   Web of Science ®Google Scholar
• Shibre T, Negash A, Kullgren G, et al. Perception of stigma among family members of individuals with schizophrenia and major affective disorders in rural Ethiopia. Soc Psychiatry Psychiatr Epidemiol. 2001;36(6):299–303.
   PubMed Web of Science ®Google Scholar
• Amador XF, Strauss DH. Poor insight in schizophrenia. Psychiatr Q. 1993;64(4):305–318.
   PubMedGoogle Scholar
• Lysaker PH, Clements CA, Plascak-Hallberg CD, et al. Insight and personal narratives of illness in schizophrenia. Psychiatry. 2002;65(3):197–206.
   PubMed Web of Science ®Google Scholar
• Bartko G, Herczeg I, Zador G. Clinical symptomatology and drug compliance in schizophrenic patients. Acta Psychiatr Scand. 1988;77(1):74–76.
   Web of Science ®Google Scholar
• Lysaker PH, Buck KD, Salvatore G, et al. Lack of awareness of illness in schizophrenia: conceptualizations, correlates and treatment approaches. Expert Rev Neurother. 2009;9(7):1035–1043.
   PubMed Web of Science ®Google Scholar
• Nageotte C, Sullivan G, Duan N, et al. Medication compliance among the seriously mentally ill in a public mental health system. Soc Psychiatry Psychiatr Epidemiol. 1997;32(2):49–56.
   Web of Science ®Google Scholar
• Lysaker PH, Dimaggio G, Buck KD, et al. Poor insight in schizophrenia: links between different forms of metacognition with awareness of symptoms, treatment need, and consequences of illness. Compr Psychiatry. 2011;52(3):253–260.
   PubMed Web of Science ®Google Scholar
• Winton-Brown TT, Elanjithara T, Power P, et al. Five-fold increased risk of relapse following breaks in antipsychotic treatment of first episode psychosis. Schizophr Res. 2017;179:50–56.
   Web of Science ®Google Scholar
• Kane JM, Kishimoto T, Correll CU. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry. 2013;12(3):216–226.
   PubMed Web of Science ®Google Scholar
• Hui CLM, Honer WG, Lee EHM, et al. Long-term effects of discontinuation from antipsychotic maintenance following first-episode schizophrenia and related disorders: a 10 year follow-up of a randomised, double-blind trial. Lancet Psychiatry. 2018;5(5):432–442.
   PubMed Web of Science ®Google Scholar
• Agid O, Foussias G, Remington G. Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention. Expert Opin Pharmacol. 2010;11(14):2301–2317.
   PubMed Web of Science ®Google Scholar
• Keating D, McWilliams S, Schneider I, et al. Pharmacological guidelines for schizophrenia: a systematic review and comparison of recommendations for the first episode. BMJ Open. 2017;7(1):e013881.
   PubMed Web of Science ®Google Scholar
• Lewis S, Lieberman J. CATIE and CUtLASS: can we handle the truth? Br J Psychiatry. 2008;192(3):161–163.
   Web of Science ®Google Scholar
• Kishi T, Matsui Y, Matsuda Y, et al. Efficacy, tolerability, and safety of blonanserin in schizophrenia: an updated and extended systematic review and meta-analysis of randomized controlled trials. Pharmacopsychiatry. 2018;52(2):52–62.
   Web of Science ®Google Scholar
• Deeks ED, Keating GM. Blonanserin: a review of its use in the management of schizophrenia. CNS Drugs. 2010;24(1):65–84.
   Web of Science ®Google Scholar
• Kishi T, Matsuda Y, Nakamura H, et al. Blonanserin for schizophrenia: systematic review and meta-analysis of double-blind, randomized, controlled trials. J Psychiatr Res. 2013;47(2):149–154.
   Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic criteria from DSM-IV-TR. Washington (DC): American Psychiatric Association; 2000.
   Google Scholar
• Howes OD, McCutcheon R, Agid O, et al. Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on diagnosis and terminology. Am J Psychiatry. 2017;174(3):216–229.
   PubMed Web of Science ®Google Scholar
• Csernansky JG, Mahmoud R, Brenner R, et al. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med. 2002;346(1):16–22.
   PubMed Web of Science ®Google Scholar
• Kim SW, Lee BJ, Kim JJ, et al. Design and methodology of the Korean early psychosis cohort study. Psychiatry Investig. 2017;14(1):93–99.
   Web of Science ®Google Scholar
• Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–276.
   PubMed Web of Science ®Google Scholar
• Rapoport J, Conners C, Reatig NJPB, National Institute of Mental Health (NIMH). Clinical global impressions. Psychopharmacol Bull. 1985;21(4):839–843.
   Google Scholar
• Correll CU, Kishimoto T, Nielsen J, et al. Quantifying clinical relevance in the treatment of schizophrenia. Clin Ther. 2011;33(12):B16–B39.
   PubMed Web of Science ®Google Scholar
• Emsley R, Hargarter L, Bergmans P, et al. Once-monthly paliperidone palmitate in early stage schizophrenia – a retrospective, non-interventional 1-year study of patients with newly diagnosed schizophrenia. Neuropsychiatr Dis Treat. 2017;13:2261–2269.
   PubMed Web of Science ®Google Scholar
• Chen EY, Hui CL, Dunn EL, et al. A prospective 3-year longitudinal study of cognitive predictors of relapse in first-episode schizophrenic patients. Schizophr Res. 2005;77(1):99–104.
   PubMed Web of Science ®Google Scholar
• Emsley R, Chiliza B, Asmal L, et al. The nature of relapse in schizophrenia. BMC Psychiatry. 2013;13:50.
   PubMed Web of Science ®Google Scholar
• Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371(9618):1085–1097.
   PubMed Web of Science ®Google Scholar
• Bostwick JR, Guthrie SK, Ellingrod VL. Antipsychotic-induced hyperprolactinemia. Pharmacotherapy. 2009;29(1):64–73.
   PubMed Web of Science ®Google Scholar
• Bushe CJ, Bradley A, Pendlebury J. A review of hyperprolactinaemia and severe mental illness: are there implications for clinical biochemistry? Ann Clin Biochem. 2010;47(Pt 4):292–300.
   PubMed Web of Science ®Google Scholar
• Takahashi S, Suzuki M, Uchiyama M. One-year follow-up of serum prolactin level in schizophrenia patients treated with blonanserin: a case series. Psychiatry Investig. 2015;12(4):566–568.
   Web of Science ®Google Scholar
• Kawabe K, Horiuchi F, Ueno S. Blonanserin, a novel antipsychotic, is suitable for treating schizophrenia associated with hyperprolactinemia: a case series. Clin Neuropharmacol. 2013;36(6):239–241.
   Web of Science ®Google Scholar
• Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs. 2007;21(11):911–936.
   PubMed Web of Science ®Google Scholar
• Fujita Y, Bessho K, Miyazaki T, et al. Comparative effectiveness of blonanserin and paliperidone in 93 in-patients with acute- to maintenance-phase schizophrenia. Clin Neuropsychopharmacol Ther. 2016;7:20–35.
   Google Scholar
• Clineschmidt BV, Lotti VJ. Histamine: intraventricular injection suppresses ingestive behavior of the cat. Arch Int Pharmacodyn Ther. 1973;206(2):288–298.
   Google Scholar
• Sakata T, Yoshimatsu H, Kurokawa M. Hypothalamic neuronal histamine: implications of its homeostatic control of energy metabolism. Nutrition. 1997;13(5):403–411.
   Web of Science ®Google Scholar